We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 357

Yeda Research and Development Co., Ltd. v. Mylan Pharmaceuticals Inc. & Teva Pharmaceuticals USA, Inc. v. Sandoz Inc.
  • Knobbe Martens
  • USA
  • October 15 2018

Non-prior art evidence may be considered when evaluating the knowledge, motivations, and expectations of a POSITA regarding the prior art. In addition


Roche Molecular Systems, Inc. v. Cepheid
  • Knobbe Martens
  • USA
  • October 11 2018

Testing for the presence of a bacterium that causes tuberculosis and the primers used in that testing were directed to patent-ineligible subject


Data Engine Technologies LLC v. Google LLC
  • Knobbe Martens
  • USA
  • October 11 2018

A claim that recites a specific method for navigating through three-dimensional electronic spreadsheets is not directed to an abstract idea. Data


Protecting Your Claimed Ranges
  • Knobbe Martens
  • USA
  • October 9 2018

Assertions of obviousness based on prior art references in combination with “routine optimization” by one skilled in the art are common in the


Real Foods Pty Ltd. v. Frito-Lay North America, Inc.
  • Knobbe Martens
  • USA
  • October 5 2018

To determine whether a mark is generic, the TTAB must first properly identify the genus of the goods at issue. The genus must be based on the


Natural Alternatives Int'l, Inc. v. IANCU
  • Knobbe Martens
  • USA
  • October 2 2018

Removing the priority claim of one application in a chain can affect the ability of pending and subsequently filed applications to claim priority to


Gust, Inc. v. Alphacap Ventures Llc
  • Knobbe Martens
  • USA
  • October 1 2018

A non-practicing entity AlphaCap, represented by Gutride Safier LLP, sued ten internet crowd-funding companies for infringement of AlphaCap’s patents


E.I. Dupont De Nemours & Co. v. Synvina C.V.
  • Knobbe Martens
  • USA
  • September 18 2018

When the ranges identified in a claimed composition overlap with the ranges disclosed in the prior art, the burden shifts to the patentee to come


UC v. Broad Institute: No Interference-In-Fact in CRISPR Genome Editing Applications
  • Knobbe Martens
  • USA
  • September 12 2018

On September 10, 2018, the Federal Circuit decided Regents of the University of California v. Broad Institute, Inc., affirming the Patent Trial and


Acorda Therapeutics, Inc.. v. Roxane Laboratories, Inc.
  • Knobbe Martens
  • USA
  • September 11 2018

Pharmaceutical patents were obvious where the claims covered species of a genus taught by the prior art, the prior art taught achieving the claimed